利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.029 秒)

    MULTICISTRONIC VECTORS AND METHODS FOR THEIR DESIGN
    2.
    发明申请
    MULTICISTRONIC VECTORS AND METHODS FOR THEIR DESIGN 审中-公开
    多媒体矢量及其设计方法

    公开(公告)号：US20090131355A1

    公开(公告)日：2009-05-21

    申请号：US12126855

    申请日：2008-05-23

    申请人： Adrian Ion Bot ,  David C. Diamond ,  Zhiyong Qiu

    发明人： Adrian Ion Bot ,  David C. Diamond ,  Zhiyong Qiu

    IPC分类号： A61K31/7088 ,  C12N15/63 ,  C12N5/10

    CPC分类号： C12N15/111 ,  A61K39/00 ,  C12N15/1135 ,  C12N15/85 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/53 ,  C12N2330/30 ,  C12N2840/20

    摘要： Embodiments of the present invention relate to multicistronic vectors and methods for their design. Methods and compositions of the invention include a vector including at least two cistrons, wherein a first cistron includes a first promoter and a first nucleic acid sequence encoding one or more therapeutic agents, and wherein a second cistron comprises a second promoter and a second nucleic acid sequence encoding one or more RNA molecules that interfere with the expression of a biological response modifier or the therapeutic agent, wherein the expression of the first sequence is under control of the first promoter and expression of the second sequence is under control of the second promoter.

    摘要翻译： 本发明的实施方案涉及多顺反子载体及其设计方法。 本发明的方法和组合物包括包含至少两个顺反子的载体，其中第一顺反子包含第一启动子和编码一种或多种治疗剂的第一核酸序列，并且其中第二顺反子包含第二启动子和第二核酸 编码干扰生物反应调节剂或治疗剂表达的一种或多种RNA分子的序列，其中第一序列的表达受第一启动子的控制，第二序列的表达受第二启动子的控制。

    CANCER IMMUNOTHERAPY AND METHOD OF TREATMENT
    4.
    发明申请
    CANCER IMMUNOTHERAPY AND METHOD OF TREATMENT 审中-公开
    癌症免疫治疗和治疗方法

    公开(公告)号：US20110274723A1

    公开(公告)日：2011-11-10

    申请号：US12910778

    申请日：2010-10-22

    申请人： Adrian Ion Bot ,  Zhiyong Qiu ,  David C. Diamond ,  Mihail Obrocea

    发明人： Adrian Ion Bot ,  Zhiyong Qiu ,  David C. Diamond ,  Mihail Obrocea

    IPC分类号： A61K39/00 ,  A61P37/04 ,  A61P35/00

    CPC分类号： A61K39/0011 ,  A61K2039/53 ,  A61K2039/545

    摘要： The instant disclosure relates to methods for treating a cancer patient with an active immunotherapeutic, wherein the methods include assessing a patient's pre-existing immunoreactivity to at least one target antigen, choosing an immunotherapeutic regimen based on the level of pre-existing immunoreactivity, and administering an active immunotherapeutic according to the regimen.

    摘要翻译： 本公开涉及用于治疗具有活性免疫治疗剂的癌症患者的方法，其中所述方法包括评估患者对至少一种靶抗原的预先存在的免疫反应性，基于预先存在的免疫反应性的水平选择免疫治疗方案，以及施用 根据该方案的主动免疫治疗。

    MULTICISTRONIC VECTORS AND METHODS FOR THEIR DESIGN
    5.
    发明申请
    MULTICISTRONIC VECTORS AND METHODS FOR THEIR DESIGN 审中-公开
    多媒体矢量及其设计方法

    公开(公告)号：US20110230548A1

    公开(公告)日：2011-09-22

    申请号：US13032635

    申请日：2011-02-22

    申请人： Adrian Ion Bot ,  David C. Diamond ,  Zhiyong Qiu

    发明人： Adrian Ion Bot ,  David C. Diamond ,  Zhiyong Qiu

    IPC分类号： A61K48/00 ,  C12N15/85 ,  C12N5/10 ,  C12N15/86

    CPC分类号： C12N15/111 ,  A61K39/00 ,  C12N15/1135 ,  C12N15/85 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/53 ,  C12N2330/30 ,  C12N2840/20

    摘要： Embodiments of the present invention relate to multicistronic vectors and methods for their design. Methods and compositions of the invention include a vector including at least two cistrons, wherein a first cistron includes a first promoter and a first nucleic acid sequence encoding one or more therapeutic agents, and wherein a second cistron comprises a second promoter and a second nucleic acid sequence encoding one or more RNA molecules that interfere with the expression of a biological response modifier or the therapeutic agent, wherein the expression of the first sequence is under control of the first promoter and expression of the second sequence is under control of the second promoter.

    摘要翻译： 本发明的实施方案涉及多顺反子载体及其设计方法。 本发明的方法和组合物包括包含至少两个顺反子的载体，其中第一顺反子包含第一启动子和编码一种或多种治疗剂的第一核酸序列，并且其中第二顺反子包含第二启动子和第二核酸 编码干扰生物反应调节剂或治疗剂表达的一种或多种RNA分子的序列，其中第一序列的表达在第一启动子的控制下，第二序列的表达受第二启动子的控制。

    Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
    6.
    发明授权
    Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma 失效
    在癌细胞和肿瘤基质上表达的显性和亚显性表位引发多价免疫应答的方法和组合物

    公开(公告)号：US08674081B2

    公开(公告)日：2014-03-18

    申请号：US13179042

    申请日：2011-07-08

    申请人： Zhiyong Qiu ,  Adrian Ion Bot

    发明人： Zhiyong Qiu ,  Adrian Ion Bot

    IPC分类号： C07H21/02

    CPC分类号： A61K39/0011 ,  A61K2039/53 ,  A61K2039/545 ,  A61K2039/70 ,  C07K14/4748 ,  C07K14/705

    摘要： The present invention provides a method of treating cancer by providing to a subject in need thereof an immunogenic composition comprising a nucleic acid construct encoding a polypeptide comprising CTL epitopes PSMA288-297 and PRAME425-433, or a cross-reactive analogue. In embodiments of the present invention there is provided methods and compositions for inducing, entraining, and/or amplifying the immune response to MHC class-I restricted epitopes of carcinoma antigens to generate an effective anti-cancer immune response.

    摘要翻译： 本发明提供了一种通过向有需要的受试者提供包含编码包含CTL表位PSMA288-297和PRAME425-433或交叉反应性类似物的多肽的核酸构建体的免疫原性组合来治疗癌症的方法。 在本发明的实施方案中，提供了用于诱导，携带和/或扩增针对癌抗原的MHC I类限制性表位的免疫应答以产生有效抗癌免疫应答的方法和组合物。

    METHODS AND COMPOSITIONS TO ELICIT MULTIVALENT IMMUNE RESPONSES AGAINST DOMINANT AND SUBDOMINANT EPITOPES, EXPRESSED ON CANCER CELLS AND TUMOR STROMA
    7.
    发明申请
    METHODS AND COMPOSITIONS TO ELICIT MULTIVALENT IMMUNE RESPONSES AGAINST DOMINANT AND SUBDOMINANT EPITOPES, EXPRESSED ON CANCER CELLS AND TUMOR STROMA 失效
    针对癌细胞和肿瘤细胞表达的主要和亚细胞抗原决定多种免疫应答的方法和组合

    公开(公告)号：US20110269949A1

    公开(公告)日：2011-11-03

    申请号：US13179042

    申请日：2011-07-08

    申请人： Zhiyong Qiu ,  Adrian Ion Bot

    发明人： Zhiyong Qiu ,  Adrian Ion Bot

    IPC分类号： C07H21/04

    CPC分类号： A61K39/0011 ,  A61K2039/53 ,  A61K2039/545 ,  A61K2039/70 ,  C07K14/4748 ,  C07K14/705

    摘要： The present invention provides a method of treating cancer by providing to a subject in need thereof an immunogenic composition comprising a nucleic acid construct encoding a polypeptide comprising CTL epitopes PSMA288-297 and PRAME425-433, or a cross-reactive analogue. In embodiments of the present invention there is provided methods and compositions for inducing, entraining, and/or amplifying the immune response to MHC class-I restricted epitopes of carcinoma antigens to generate an effective anti-cancer immune response.

    摘要翻译： 本发明提供了一种通过向有需要的受试者提供包含编码包含CTL表位PSMA288-297和PRAME425-433或交叉反应性类似物的多肽的核酸构建体的免疫原性组合来治疗癌症的方法。 在本发明的实施方案中，提供了用于诱导，携带和/或扩增针对癌抗原的MHC I类限制性表位的免疫应答以产生有效的抗癌免疫应答的方法和组合物。

    Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
    8.
    发明授权
    Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma 有权
    在癌细胞和肿瘤基质上表达的显性和亚显性表位引发多价免疫应答的方法和组合物

    公开(公告)号：US07999088B2

    公开(公告)日：2011-08-16

    申请号：US11454616

    申请日：2006-06-16

    申请人： Zhiyong Qiu ,  Adrian Ion Bot

    发明人： Zhiyong Qiu ,  Adrian Ion Bot

    IPC分类号： C07H21/02 ,  C12K15/11

    CPC分类号： A61K39/0011 ,  A61K2039/53 ,  A61K2039/545 ,  A61K2039/70 ,  C07K14/4748 ,  C07K14/705

    摘要： The present invention provides a method of treating cancer by providing to a subject in need thereof an immunogenic composition comprising a nucleic acid construct encoding a polypeptide comprising CTL epitopes PSMA288-297 and PRAME425-433, or a cross-reactive analogue. In embodiments of the present invention there is provided methods and compositions for inducing, entraining, and/or amplifying the immune response to MHC class-I restricted epitopes of carcinoma antigens to generate an effective anti-cancer immune response.

    摘要翻译： 本发明提供了一种通过向有需要的受试者提供包含编码包含CTL表位PSMA288-297和PRAME425-433或交叉反应性类似物的多肽的核酸构建体的免疫原性组合来治疗癌症的方法。 在本发明的实施方案中，提供了用于诱导，携带和/或扩增针对癌抗原的MHC I类限制性表位的免疫应答以产生有效的抗癌免疫应答的方法和组合物。

    Methods to bypass CD4+ cells in the induction of an immune response
    9.
    发明申请
    Methods to bypass CD4+ cells in the induction of an immune response 失效
    绕过CD4 +的方法

    公开(公告)号：US20080124352A1

    公开(公告)日：2008-05-29

    申请号：US11323520

    申请日：2005-12-29

    申请人： David C. Diamond ,  Adrian Ion Bot

    发明人： David C. Diamond ,  Adrian Ion Bot

    IPC分类号： A61K39/00 ,  A61K31/70 ,  A61P43/00

    CPC分类号： A61K39/0011 ,  A61K39/12 ,  A61K39/21 ,  A61K39/292 ,  A61K39/39 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/55561 ,  A61K2039/57 ,  C12N2730/10134 ,  C12N2740/16234

    摘要： Embodiments of the invention disclosed herein relate to methods and compositions for bypassing the involvement of CD4+ cells when generating antibody and MHC class I-restricted immune responses, controlling the nature and magnitude of the response, and promoting effective immunologic intervention in viral pathogenesis. More specifically, embodiments relate to immunogenic compositions for vaccination particularly therapeutic vaccination, against HIV and other microbial pathogens that impact functioning of the immune system, their nature, and the order, timing, and route of administration by which they are effectively used.

    摘要翻译： 本文公开的本发明的实施方案涉及用于在产生抗体和MHC I类限制性免疫应答时绕过CD4 +细胞的参与的方法和组合物，控制反应的性质和量值，以及促进对病毒发病机理的有效免疫干预。 更具体地，实施方案涉及针对HIV和其它影响免疫系统功能的其它微生物病原体的疫苗接种的免疫原性组合物，其性质以及它们有效使用的给药顺序，时间和途径。

    Methods to bypass CD4+ cells in the induction of an immune response
    10.
    发明授权
    Methods to bypass CD4+ cells in the induction of an immune response 失效
    避免CD4 +细胞诱导免疫反应的方法

    公开(公告)号：US08703142B2

    公开(公告)日：2014-04-22

    申请号：US11323520

    申请日：2005-12-29

    申请人： David C. Diamond ,  Adrian Ion Bot

    发明人： David C. Diamond ,  Adrian Ion Bot

    IPC分类号： A61K39/00 ,  A61K48/00

    CPC分类号： A61K39/0011 ,  A61K39/12 ,  A61K39/21 ,  A61K39/292 ,  A61K39/39 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/55561 ,  A61K2039/57 ,  C12N2730/10134 ,  C12N2740/16234

    摘要： Embodiments of the invention disclosed herein relate to methods and compositions for bypassing the involvement of CD4+ cells when generating antibody and MHC class I-restricted immune responses, controlling the nature and magnitude of the response, and promoting effective immunologic intervention in viral pathogenesis. More specifically, embodiments relate to immunogenic compositions for vaccination particularly therapeutic vaccination, against HIV and other microbial pathogens that impact functioning of the immune system, their nature, and the order, timing, and route of administration by which they are effectively used.

    摘要翻译： 本文公开的本发明的实施方案涉及用于在产生抗体和MHC I类限制性免疫应答时绕过CD4 +细胞的参与的方法和组合物，控制反应的性质和量值，以及促进对病毒发病机理的有效免疫干预。 更具体地，实施方案涉及针对HIV和其它影响免疫系统功能的其它微生物病原体的疫苗接种的免疫原性组合物，其性质以及它们有效使用的给药顺序，时间和途径。